Global Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global pre-exposure prophylaxis HIV drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Pre-exposure prophylaxis drugs are the medicines that are to be taken so as to prevent infection with HIV. Pre-exposure prophylaxis is highly effective for preventing HIV when taken as prescribed. The major driving factors contributing to the market growth include the rising prevalence and burden of HIV, growing investment in R&D related to these drugs coupled with the rise in the availability of novel drugs that pose better efficacy than ever before. For instance, as per the US Department of Health & Human Services, in 2018, there were nearly 37.9 million people globally living with HIV/AIDS. An estimated 1.7 million individuals globally became newly infected with HIV in 2018.
To Request a Sample of our Report on Global Pre-Exposure
Prophylaxis (PrEP) HIV Drugs Market: https://www.omrglobal.com/request-sample/pre-exposure-prophylaxis-hiv-drugs-market
These drugs are majorly available in a number of
categories that broadly include Integrase Inhibitors, Protease Inhibitors,
Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors
(NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and others.
Currently, pre-exposure prophylaxis drugs are considered to be the basis of
HIV/AIDS treatment, since there is no solid cure or a preventive vaccine
available for HIV. Thus, the presence of a huge patient pool leads to
increasing demand for pre-exposure prophylaxis drugs for the treatment of HIV,
which is projected to drive the growth of the market during the forecast
period.
Some key players operating in the market include
Gilead Sciences, Inc., Mylan N.V., and Cipla Ltd., among others. These market
players are focusing on strengthening their position in the market by adopting
various strategies such as mergers and acquisitions, partnerships and
collaborations, new product launches and development in the existing product
portfolio, and so on. In May 2019, Gilead Sciences, Inc. declared that it will
donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate
300 mg tablets) to the US Centers for Disease Control and Prevention (CDC) in
support of national efforts to help prevent HIV and end the epidemic. This is
part of Gilead’s wide ongoing initiatives to support ensure that everyone who
can benefit from PrEP can access it. Gilead will provide to CDC up to 2.4
million bottles of Truvada annually for uninsured Americans at risk for
HIV.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Gilead Sciences,
Inc., Mylan N.V., and Cipla Ltd., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market is
Available at: https://www.omrglobal.com/industry-reports/pre-exposure-prophylaxis-hiv-drugs-market
Global Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market Report by Segment
By Drugs
• Truvada
• Descovy
By Dosage Form
• Oral
• Topical
Global Pre-Exposure Prophylaxis (PrEP) HIV Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment